Page 124 - 2019_03-Haematologica-web

E. Brissot et al.
Table 4. Multivariate analysis for leukemia-free survival, overall sur- vival, relapse incidence, non-relapse mortality and graft-versus-host disease-free, relapse-free survival.
continued from the previous coloum
0.71 - 0.99
0.8 - 1.17 NS
HR CI Pvalue
HR CI Pvalue
Sequential strategy versus MAC 1.07 Poor cytogenetics 1.48 Karnofsky Performance Score ≥90 0.76 Stem cell source: PBS versus BM 0.90 Previous autologous transplant 0.99 Female to male ratio 0.89
0.85 - 1.36 NS 1.18 - 1.85 <10-3
Leukemia-free survival
UD 10/10 versus Haplo 0.97
UD 9/10 versus Haplo 1.05
Disease status: PRF-AML 1 1st relapse versus PRF-AML 1.10 2nd relapse versus PRF-AML 1.31
Time from diagnosis to transplant 0.99
Age at transplant (per 10 years) 1.00
Year of transplant 1.00
Conditioning regimen (ref=MAC) 1 RIC versus MAC 0.84 Sequential strategy versus MAC 0.97
Poor cytogenetics 1.35 Karnofsky Performance Score ≥90 0.66 Stem cell source: PBS versus BM 0.97 Previous autologous transplant 0.95 Female to male ratio 0.89 Patient CMV positive 1.22 Donor CMV positive 0.99 Center (frailty)
Overall survival
UD 10/10 versus Haplo 0.98
UD 9/10 versus Haplo 1.05
Disease status: PRF-AML 1 1st relapse versus PRF-AML 1.14 2nd relapse versus PRF-AML 1.35
Time from diagnosis to transplant 0.99
Age at transplant (per 10 years) 1.04
Year of transplant 1.00
Conditioning regimen (ref=MAC) 1 RIC versus MAC 0.74 Sequential strategy versus MAC 0.91
Poor cytogenetics 1.28 Karnofsky Performance Score ≥90 0.62 Stem cell source: PBS versus BM 0.97 Previous autologous transplant 0.94 Female to male ratio 0.90 Patient CMV positive 1.27 Donor CMV positive 0.96 Center (frailty)
Relapse incidence
UD 10/10 versus Haplo 0.92
UD 9/10 versus Haplo 1.03
Disease status: PRF-AML 1 1st relapse versus PRF-AML 1.32 2nd relapse versus PRF-AML 1.64
Time from diagnosis to transplant 0.98
Age at transplant (per 10 years) 0.92
Year of transplant 0.98
Conditioning regimen (ref=MAC) 1 RIC versus MAC 0.97
0.75 - 1.24 NS
0.80 - 1.37 NS 0.95 - 1.28 NS
0.64 - 0.90
0.001
1.03 - 1.65
0.98 - 0.99
0.95 - 1.05
0.97 - 1.03 NS
0.69 - 1.18 NS
0.65 - 1.54 NS
0.71 - 1.12 NS
0.96 - 1.38 NS
0.82 - 1.15 NS
<10-3
0.67 - 1.52 NS
0.66 - 1.61 NS
0.70 - 1.12 NS 0.71 - 1.50 NS
0.99 - 1.01 NS 1.08 - 1.28 <10-3 0.99 - 1.09 NS
0.03 Patient CMV positive 1.15 0.02 Donor CMV positive 0.97
NS Center (frailty)
Non-relapse mortality
0.03 UD 10/10 versus Haplo 1.01
UD 9/10 versus Haplo 1.03
1.11- 1.62
0.58 - 0.76
0.78 - 1.21 NS
0.68 - 1.33 NS
0.74 - 1.06 NS
1.05 - 1.41 0.01
0.87 - 1.14 NS
<10-3
0.75 - 1.27 NS
0.79 - 1.39 NS
0.002
<10-3 1st relapse versus PRF-AML 0.88
Disease status: PRF-AML 1
2nd relapse versus PRF-AML 1.03 Time from diagnosis to transplant 1.00 Age at transplant (per 10 years) 1.18 Year of transplant 1.04
Conditioning regimen (ref=MAC) 1 RIC versus MAC 0.64 Sequential strategy versus MAC 0.80
Poor cytogenetics 1.10 Karnofsky Performance Score ≥90 0.52 Stem cell source: PBS versus BM 1.19 Previous autologous transplant 0.99
0.49 - 0.84
0.59 - 1.09 NS
0.79 - 1.55 NS 0.41 - 0.64 <10-3 0.81 - 1.75 NS 0.57 - 1.72 NS 0.63 - 1.18 NS 1.07 - 1.77 0.01 0.83 - 1.29 NS
NS
0.87 - 1.39 NS
0.86 - 1.43 NS
0.91 - 1.21 NS 0.98 - 1.52 NS
0.98 - 0.99 0.02 0.93 - 1.02 NS 0.99- 1.05 NS
0.001
0.97 - 1.33 1.05 - 1.72
NS Female to male 0.87 0.018 Patient CMV positive 1.37 0.02 Donor CMV positive 1.03
NS Center (frailty)
GRFS
<10-3 UD 10/10 versus Haplo 1.09 NS UD 9/10 versus Haplo 1.11
0.01 Disease status: PRF-AML 1 <10-3 1st relapse versus PRF-AML 1.05
0.99 - 1.00
0.99 - 1.10
0.97 - 1.03 NS
0.62 - 0.88 0.75 - 1.12
1.06 - 1.56
0.54 - 0.71
0.77 - 1.22 NS 0.66 - 1.35 NS 0.75 - 1.09 NS
2nd relapse versus PRF-AML 1.22 Time from diagnosis to transplant 0.99 Age at transplant (per 10 years) 0.98 Year of transplant 1.02
1.09 - 1.49
0.83 - 1.11 NS
0.002
Conditioning regimen (ref=MAC) 1 RIC versus MAC 0.86 <10-3 Sequential strategy versus MAC 0.93
0.74 - 0.99
0.78 - 1.11 NS
0.67 - 1.25 NS
0.74 - 1.47 NS
1.09 - 1.60 1.21 - 2.21
0.79 - 1.19 NS
continued in the next coloum
1.00 - 1.44
0.60 - 0.77 <10-3 0.94 - 1.42 NS 0.69 - 1.31 NS 0.71 - 1.01 NS 0.99 - 1.31 NS 0.86 - 1.12 NS
0.01
Poor cytogenetics 1.20 Karnofsky Performance Score ≥90 0.68 Stem cell source: PB versus BM 1.15 Previous autologous transplant 0.95 Female to male ratio 0.85
0.047 0.046
0.005
0.001 Patient CMV positive 1.14
<10-3 Donor CMV positive 0.98
Center (frailty)
0.97 - 0.99
0.87 - 0.98
0.94 - 1.01 NS
0.007
AML: acute myeloid leukemia; BM: bone marrow; CI: confidence interval; CMV: cytomegalovirus; haplo: haploidentical; HR: hazard ratio; MAC: myeloablative condition- ing; NS: not significant; PB: peripheral blood PRF-AML; PRF: primary refractory acute myeloid leukemia; Rel: relapse; RIC: reduced intensity conditioning; UD: unrelated donor.
530